Click here for PDF
(CHICAGO) September 26, 2019 – Steven Trybus, a veteran litigator who focuses on complex patent disputes, has joined Locke Lord’s Chicago office as a Partner in the Firm’s IP Pharmaceutical Practice Group. Trybus brings to Locke Lord a wealth of litigation experience across a variety of cutting-edge technologies in the fields of pharmaceuticals, biotechnology and life sciences.
Trybus is a distinguished lawyer in the defense of patents for the groundbreaking CRISPR gene-editing technology, which allows for the permanent modification of human, animal and plant genes to avoid, prevent or cure disease or undesirable traits. Trybus has also handled matters involving pharmaceuticals and medical devices; the chemical arts, such as polymers; electronics, including software and telecommunications; and mechanical devices, such as food processing equipment.
“Steve is at the forefront of patent disputes for revolutionary technologies, including CRISPR, which will be integral to broadening our IP practice and reputation in Chicago and nationally,” said Keith Parr, Co-Chair of Locke Lord’s IP Pharmaceutical Practice Group and a Partner in the Firm’s Chicago office. “His technical skill adds strength to our already robust IP Pharma capabilities, and his arrival exhibits Locke Lord’s commitment to remaining a leading law firm for clients in the pharmaceutical industry, one of the Firm’s Key Sectors.”
Trybus, who joins Locke Lord from Jenner & Block, has more than 30 years of experience handling a wide range of patent infringement cases for both patent owners and accused infringers. He concentrates on patent litigation and related counseling with significant experience in contested proceedings in the U.S. Patent and Trademark Office. His practice includes interferences, inter partes reviews, post grant reviews and appeals.
“Locke Lord’s strong emphasis on life sciences including the pharmaceutical sector and highly regarded reputation made the Firm the ideal fit for collaboration and growth within my practice,” said Trybus. “With the support of a first-class team of lawyers renowned for its technical adeptness and experience across a variety of scientific fields, including chemistry and biotechnology, I will be able to significantly expand my client offerings. I am particularly eager to collaborate with the Firm’s esteemed life sciences lawyers in Boston and Providence, who have a history of skillfully serving innovative clients.”
Trybus has been recognized for his achievements as an Intellectual Property Trailblazer by the National Law Journal and an IP Star by Managing Intellectual Property. He is involved with the Federal Circuit Bar Association, the Intellectual Property Owners Association, the American Intellectual Property Law Association, the PTAB Bar Association, the American Association for the Advancement of Science, the American Chemical Society and the American Institute of Chemical Engineers.
Locke Lord’s IP Pharmaceutical Practice combines strong scientific understanding, courtroom experience, regulatory experience and industry knowledge. The Firm’s lawyers have technical skills and specific experience in a variety of scientific fields, including: pharmaceuticals; organic, inorganic and industrial chemistry; biochemistry; biotechnology; and genetics. Many of Locke Lord’s lawyers and scientific advisors have doctorate degrees in the chemical and biological arts. Their real world experience enables them to counsel clients on virtually any legal issue surrounding a lawsuit or transaction without losing sight of the science or technology involved. Pharmaceutical and biotechnology companies turn to Locke Lord for assistance in structuring transactions, building strategically solid portfolios and identifying and protecting IP rights.
About Locke Lord LLP
Locke Lord is a full-service law firm with global reach and 20 offices designed to meet clients’ needs in the United States and around the world. The Firm has a history that spans more than 130 years and is a leader in the middle market arena. Locke Lord focuses on providing the highest levels of commitment, quality and service to clients across its five Key Sectors: Energy and Infrastructure; Finance and Financial Services; Insurance and Reinsurance; Pharmaceutical; and Private Equity. In addition, the Firm advises clients across a broad spectrum of other industries, including fund formation, venture capital, health care, public finance, real estate, technology, cybersecurity and white collar, while providing a wealth of experience through its complex litigation, intellectual property, tax, regulatory and transactional teams.